Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2

Cancer

Volumn 120, Issue 10, 2014, Pages 1557-1564

  Jackson, Sarah A ^a   Davis, Andrew A ^a   Li, Jun ^b   Yi, Nengjun ^b   McCormick, Shelley R ^c   Grant, Carly ^c   Fallen, Taya ^a   Crawford, Beth ^d   Loranger, Kate ^d   Litton, Jennifer ^e   Arun, Banu ^e   Vande Wydeven, Kimberly ^f   Sidani, Amer ^f   Farmer, Katie ^g   Sanders, Merideth ^g   Hoskins, Kent ^f   Nussbaum, Robert ^d   Esserman, Laura ^d   Garber, Judy E ^c   Kaklamani, Virginia G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

BART; BRCA1; BRCA2; breast cancer; breast cancer rearrangement mutations; mutations

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BRACANALYSIS LARGE REARRANGEMENT TEST; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HIGH RISK PATIENT; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL HISTORY; ONSET AGE; OVARY CANCER; PANCREAS CANCER; POPULATION GENETICS; PRIORITY JOURNAL; PROGESTERONE RECEPTOR NEGATIVE BREAST CANCER; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

BART; BRCA1; BRCA2; BREAST CANCER; BREAST CANCER REARRANGEMENT MUTATIONS; MUTATIONS;

ADENOCARCINOMA, MUCINOUS; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CARIBBEAN REGION; CARRIER PROTEINS; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENE DELETION; GENE DUPLICATION; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HISPANIC AMERICANS; HUMANS; JEWS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84899991774     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28577     Document Type: Article

References (20)

1. Campeau PM, Foulkes WD, Tischkowitz MD,. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 2008; 124: 31-42.
2. BRACAnalysis® Large Rearrangement Test (BART™). Salt Lake City, UT: Myriad Genetics, Inc; 2013. https://www.myriad.com/lib/brac/BART-faq.pdf.
3. Armour JA, Barton DE, Cockburn DJ, Taylor GR,. The detection of large deletions or duplications in genomic DNA. Hum Mutat. 2002; 20: 325-337.
4. Judkins T, Rosenthal E, Arnell C, et al. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer. 2012; 118: 5210-5216.
5. Weitzel JN, Clague J, Martir-Negron A, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol. 2013; 31: 210-216.
6. BRCA risk calculator. 2013. https://www.myriadpro.com/hereditary-cancer- testing/hereditary-breast-and-ovarian-cancer-hboc-syndrome/brca-risk-calculator/ . Accessed December 2013.
7. Myriad Genetic Laboratories, Inc. BRCA1 and BRCA2 Prevalence Tables for Mutations Detected by Sequencing, the 5-site Rearrangement Panel (LRP) and the BRACAnalysis® Large Rearrangement Test (BART™) in High Risk Patients. https://www.myriad.com/lib/brac/BART-table-faq.pdf. Accessed December 2013.
8. Becker T, Schumacher J, Cichon S, Baur MP, Knapp M,. Haplotype interaction analysis of unlinked regions. Genet Epidemiol. 2005; 29: 313-322.
9. Hein R, Beckmann L, Chang-Claude J,. Comparison of different haplotype-based association methods for gene-environment (GxE) interactions in case-control studies when haplotype-phase is ambiguous. Hum Hered. 2009; 68: 252-267.
10. Kwee LC, Epstein MP, Manatunga AK, Duncan R, Allen AS, Satten GA,. Simple methods for assessing haplotype-environment interactions in case-only and case-control studies. Genet Epidemiol. 2007; 31: 75-90.
11. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered. 2003; 55: 56-65.
12. Yi N, Banerjee S,. Hierarchical generalized linear models for multiple quantitative trait locus mapping. Genetics. 2009; 181: 1101-1113.
13. Gelman A, Jakulin A, Pittau MG, Su YS,. A weakly informative default prior distribution for logistic and other regression models. Ann Appl Stat. 2013; 2: 1360-1383.
14. Yi N, Xu S,. Bayesian LASSO for quantitative trait loci mapping. Genetics. 2008; 179: 1045-1055.
15. Stevens KN, Vachon CM, Couch FJ,. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013; 73: 2025-2030.
16. Janssens AC, Moonesinghe R, Yang Q, Steyerberg EW, van Duijn CM, Khoury MJ,. The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases. Genet Med. 2007; 9: 528-535.
17. Weitzel JN, Lagos VI, Herzog JS, et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1615-1620.
18. Mazzola E, Cheng SC, Parmigiani G,. The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2013; 137: 315-318.
19. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL,. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007; 25: 642-647.
20. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295: 1379-1388.